Geron Corporation (NASDAQ: GERN) — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. The filing was signed March 16, 2023. It reports annual results; separate fourth-quarter financial results are not provided in the supplied filing text.
Business context
Geron is a clinical-stage biopharmaceutical company focused on imetelstat, its sole product candidate, a telomerase inhibitor being developed for blood cancers. It had no approved products and no product-sales revenue. The main program was lower-risk myelodysplastic syndromes (MDS); the company also was developing imetelstat for relapsed/refractory myelofibrosis (MF) and other indications.
Financial performance and liquidity
| Metric | 2022 | 2021 | Change / context |
|---|---|---|---|
| Revenue | $0.6 million | $1.4 million | Down from royalties and license-related revenue; no imetelstat product revenue. |
| Research and development expense | $95.5 million | $85.7 million | Up 11%; increased personnel and regulatory-preparation costs, partly offset by lower manufacturing and trial costs. |
| General and administrative expense | $43.6 million | $29.7 million | Up 47%, including commercial-readiness spending, added personnel, and $6.2 million of company-borne class-action and derivative settlement costs. |
| Operating loss | $138.6 million | $114.0 million | Loss widened as operating expenses increased. |
| Net loss | $141.9 million | $116.1 million | Loss widened; basic and diluted loss per share was $0.37 versus $0.35. |
| Net cash used in operations | $127.4 million | $95.6 million | Higher spending on clinical development and headcount. |
| Cash, restricted cash and marketable securities | $173.1 million | $212.7 million | Down $39.6 million year over year. |
| Debt principal outstanding | $50.0 million | Not stated here | Balance-sheet debt carrying value was approximately $51.2 million, including accrued end-of-term charge and net discounts. |
At year-end, current assets were $180.2 million and current liabilities were $76.7 million. The company reported no product gross margin; margins are not meaningful for its current royalty-based revenue and development-stage operations. Interest expense rose to $6.9 million from $3.7 million, while interest income rose to $2.5 million from $0.5 million.
Cash flow from investing activities provided $62.1 million, largely reflecting maturities exceeding purchases of marketable securities. Financing activities provided $87.3 million, primarily from the April 2022 public offering and warrant exercises. The company had an accumulated deficit of $1.4 billion.
Material developments and outlook
- IMerge Phase 3: In January 2023, after the 2022 reporting period, Geron announced positive top-line results in lower-risk MDS. The 8-week transfusion-independence rate was 39.8% with imetelstat versus 15.0% with placebo; the 24-week rate was 28.0% versus 3.3% (p<0.001 for both). These were top-line results and remained subject to further follow-up, audit and verification.
- Safety: In IMerge, Grade 3/4 thrombocytopenia and neutropenia occurred in 61.9% and 67.8% of imetelstat-treated patients, respectively. The company reported no new safety signals; cytopenias and other adverse events remain material risks.
- Regulatory and launch plans: Management planned a U.S. NDA submission in mid-2023 and an EU marketing application in the second half of 2023. If accepted and approved on expected timelines, it anticipated a U.S. launch in the first half of 2024 and a European launch by year-end 2024. These were plans, not assured outcomes.
- Other trials: IMpactMF Phase 3 was enrolling, with an interim overall-survival analysis expected in 2024 and a final analysis in 2025 under planning assumptions. Timing is event-driven and uncertain. IMproveMF Phase 1 was enrolling; the investigator-led IMpress Phase 2 site was planned to open in 2023.
- Cash runway and financing: Following a January 2023 public offering yielding approximately $213.3 million net and $59.8 million of warrant-exercise proceeds received through March 9, management estimated funding through the end of Q3 2025, including a potential U.S. MDS launch. This estimate depends on operating assumptions and is not a guarantee. The January offering included 68.0 million common shares and a pre-funded warrant for 25.0 million shares, creating potential dilution.
- Debt availability: Up to $55.0 million remained potentially drawable under the loan facility, subject to milestones and other conditions. The filing notes uncertainty about access to this funding following the March 10, 2023 closure of Silicon Valley Bank, which held 35% of remaining commitments. Geron stated it held no deposits or securities at SVB.
- Unusual items and contingencies: Proposed settlements included a $24.0 million securities class-action settlement, of which $7.0 million was the company’s stated portion, and a $1.35 million derivative-action settlement, of which $825,000 was payable by the company. Court approval and other conditions remained outstanding at filing. The company recorded its portions in 2022 expenses and liabilities.
Key risks and management commentary
Geron is dependent on imetelstat and expects continued losses and negative operating cash flow. Key risks include failure to obtain regulatory approval; trial delays, inconclusive efficacy or adverse safety outcomes; reliance on third-party manufacturers and CROs; manufacturing capacity, cost and inspection issues; competition and reimbursement uncertainty; patent life and protection; and the need for additional capital. COVID-19, the Russia-Ukraine conflict, inflation, higher interest rates and banking-market disruption were cited as potential sources of operational, trial and financing uncertainty. The company also disclosed pending securities and derivative litigation and risks involving cybersecurity, privacy and data protection.
Management reported effective disclosure controls and internal control over financial reporting as of December 31, 2022. The independent auditor issued an unqualified opinion on the financial statements; it did not provide an internal-control attestation. Accrued clinical-trial expenses were identified as a critical audit matter because their estimation depends on trial activity and vendor services performed.
Most important facts for investors to verify
- Final, fully verified IMerge results, including durability, subgroup outcomes, safety and regulatory sufficiency.
- Actual NDA and EU application submission, acceptance, review and approval timing, plus any label or additional-study requirements.
- IMpactMF enrollment pace, interim and final event timing, and whether overall-survival results support the program.
- Cash burn and runway against actual development and launch costs; availability of remaining loan tranches and any further financing needs.
- Commercial manufacturing readiness, supply reliability, cost reductions, and resolution of the third-party manufacturer inspection deficiencies.
- Final court approvals and ultimate company cash exposure for the class-action and derivative settlements.
- Potential dilution from outstanding warrants, options, the January 2023 pre-funded warrant and future equity financing.